Thermo Fisher to drop $1.7B on gene therapy maker Brammer Bio

Thermo Fisher (NYSE:TMO) said today that it will acquire gene and cell therapy manufacturer Brammer Bio for $1.7 billion in cash.
Brammer Bio is a viral vector contract developer and manufacturer of gene therapies and gene-modified cell therapies for biopharma customers. The Cambridge, Mass.-based business has nearly 600 employees at primary locations in Massachusetts and Alachua, Fla.
Get the full story on our sister site, Medical Design & Outsourcing.
The post Thermo Fisher to drop $1.7B on gene therapy maker Brammer Bio appeared first on MassDevice.

Source: Mass Device - March 25, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Biotech Blog Business/Financial News Featured Mergers & Acquisitions News Well Outsourcing Wall Street Beat brammerbio Thermo Fisher Scientific Source Type: news